Clopidogrel
Product Images NDC 66116-494

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 66116-494). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula For Clopidogrel Bisulfate (89033966 72f2 44b3 8335 3d12e82f27fe 01)

Chemical structure of clopidogrel sulfate showing its molecular arrangement with rings and functional groups including a thiophene ring and chlorophenyl group.*

FDA Label Image

Figure 1 (89033966 72f2 44b3 8335 3d12e82f27fe 02)

A horizontal error bar chart comparing the effect of coadministered proton pump inhibitors (PPIs) Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on the active metabolite AUC of Clopidogrel. The x-axis represents the change relative to Clopidogrel administered alone, ranging from 0.4 to 1.4, with mean values and 90% confidence intervals shown for each PPI.*

FDA Label Image

Figure 2 (89033966 72f2 44b3 8335 3d12e82f27fe 03)

A line graph showing cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares two groups: placebo plus aspirin and clopidogrel plus aspirin, with event rates plotted over time and a reported p-value of 0.00009 indicating statistical significance.*

FDA Label Image

Figure 3 (89033966 72f2 44b3 8335 3d12e82f27fe 04)

A forest plot showing the hazard ratios and 95% confidence intervals for various baseline characteristics and concomitant medications comparing Clopidogrel plus aspirin to placebo. It includes demographic categories such as age, gender, race, and clinical factors like previous myocardial infarction, diabetes, and medication use, illustrating the relative effect size between Clopidogrel and placebo groups.*

FDA Label Image

Figure 3: Cumulative Event Rates For Death In The Commit Study (89033966 72f2 44b3 8335 3d12e82f27fe 05)

A Kaplan-Meier survival curve comparing the percentage of deaths before first discharge over 28 days between Clopidogrel and placebo groups. The y-axis shows % dead before first discharge, and the x-axis shows days since randomization. The graph shows lower mortality for Clopidogrel (7.5%) compared to placebo (8.1%) with a 7% proportional risk reduction.*

FDA Label Image

Figure 5 (89033966 72f2 44b3 8335 3d12e82f27fe 06)

A Kaplan-Meier curve chart showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days. It compares two groups: placebo with 10.1% event occurrence and Clopidogrel with 9.2% event occurrence, indicating a 9% proportional risk reduction (p = 0.002). The x-axis represents days since randomization, and the y-axis shows the percentage of events.*

FDA Label Image

Figure 6 (89033966 72f2 44b3 8335 3d12e82f27fe 07)

A forest plot comparing event percentages and odds ratios between Clopidogrel and placebo groups across various baseline categories including sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation. The plot shows odds ratios with confidence intervals and heterogeneity test results, illustrating the proportional reduction effect of Clopidogrel versus placebo.*

FDA Label Image

Figure 7 (89033966 72f2 44b3 8335 3d12e82f27fe 08)

A forest plot chart comparing event percentages for Clopidogrel and Placebo across different categorical variables including Killip class, previous myocardial infarction (MI), and infarct location. The chart presents odds ratios with confidence intervals and heterogeneity p-values, illustrating proportional reduction benefit of Clopidogrel with detailed subgroup analyses.*

FDA Label Image

Figure 8 (89033966 72f2 44b3 8335 3d12e82f27fe 09)

A line chart showing the cumulative event rate percentage of fatal or non-fatal vascular events over 36 months of follow-up. The chart compares two groups labeled Aspirin and Clopidogrel, with the vertical axis ranging from 0 to 16% and the horizontal axis showing months of follow-up from 0 to 36. A p-value of 0.045 is noted on the graph.*

FDA Label Image

Clopidogrel 75mg Tablets #30 (89033966 72f2 44b3 8335 3d12e82f27fe 10)

Label for Clopidogrel Tablets USP 75 mg, 30 tablets, under the MedStart Connect brand by MedVantx, Inc. Includes storage instructions (store at controlled room temperature 20°-25°C), a phone number for free shipping and home delivery, and mentions manufacturing by Teva Pharmaceuticals USA. Additional details include lot number, expiration date placeholder, and manufacturer location in Jerusalem, Israel.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.